BPC-157: What It Is, What the Research Shows, and How It’s Regulated in Australia
Published 19 September 2026
BPC-157: What It Is, What the Research Shows, and How It’s Regulated in Australia
Updated September 2026
BPC-157 is a synthetic peptide that has attracted significant interest in laboratory research and online health discussions. Research has investigated its biological effects in a range of preclinical models, particularly in relation to tissue repair and gastrointestinal and musculoskeletal systems. However, the human evidence remains limited, and BPC-157 is not an ARTG-registered medicine in Australia. This article explains what BPC-157 is, what the published research has examined, what remains uncertain, and how the substance is regulated in Australia. (Sikiric et al., 2016; Vasireddi et al., 2025; Therapeutic Goods Administration, 2026).
What is BPC-157?
BPC-157 is a synthetic 15-amino-acid peptide commonly described in the scientific literature as a stable gastric pentadecapeptide. Research has investigated the substance in experimental models involving the gastrointestinal tract, vascular signalling, inflammation, tissue injury and repair. (Sikiric et al., 2016).
The majority of the published BPC-157 literature has historically been preclinical. This includes laboratory experiments and animal studies rather than large, well-controlled clinical trials in humans. Preclinical findings can help identify biological mechanisms and potential areas for further investigation, but they do not establish that the same effects, safety profile or therapeutic outcomes will occur in humans. (Sikiric et al., 2016; Vasireddi et al., 2025).
What has BPC-157 been studied for?
Research has investigated BPC-157 in several experimental settings, including gastrointestinal injury, tissue healing, vascular signalling, inflammation and musculoskeletal injury. Much of this work has examined biological pathways involved in tissue repair rather than evaluating BPC-157 as an established clinical treatment. (Sikiric et al., 2016; Vasireddi et al., 2025).
A 2025 systematic review of the musculoskeletal literature identified 36 studies published between 1993 and 2024. The review reported that preclinical studies had investigated BPC-157 in models of muscle, tendon, ligament and bone injury and had reported effects involving growth-factor signalling and inflammatory pathways. The authors also emphasised the limited clinical evidence and the need for further research. (Vasireddi et al., 2025).
What does the human research show?
Human research on BPC-157 remains very limited compared with the volume of laboratory and animal research. The 2025 systematic review identified only a small amount of human evidence within the musculoskeletal literature, including a 12-patient case series involving chronic knee pain. The study was uncontrolled and therefore cannot establish that BPC-157 was responsible for the reported outcomes. (Vasireddi et al., 2025).
A separate 2025 pilot study investigated intravenous BPC-157 in just two adults. Participants received infusions on two consecutive days and underwent clinical observations and laboratory testing. The investigators reported no measurable adverse effects in the biomarkers examined and reported that the infusions were tolerated. The study was extremely small, involved only two participants and was designed as an early safety investigation, so its findings cannot establish the safety or effectiveness of BPC-157 for broader populations or longer-term use. (Lee & Burgess, 2025).
The distinction between these findings and established clinical evidence is important. A small pilot study can provide preliminary information for future research, but it cannot substitute for adequately powered, controlled clinical trials assessing safety, efficacy, dosing, formulation and longer-term outcomes. (Lee & Burgess, 2025; Vasireddi et al., 2025).
What remains unclear about BPC-157?
One of the major limitations of the current evidence base is the relatively small amount of human clinical research compared with the amount of preclinical research. The 2025 systematic review found that most of the available studies were conducted in animal or laboratory models, with only limited human evidence identified. (Vasireddi et al., 2025).
This means that questions remain about how BPC-157 behaves in humans, including its pharmacokinetics, appropriate formulations, dosing, longer-term safety and potential adverse effects. A 2026 review of BPC-157’s development barriers similarly highlighted gaps in pharmaceutical characterisation, pharmacokinetic information, validated formulations and clinical evidence. (Vasireddi et al., 2025; BPC-157 investigational peptide therapeutic review, 2026).
The available evidence also should not be interpreted as demonstrating that BPC-157 is an established treatment for tendon injuries, muscle injuries, gastrointestinal conditions or other medical conditions. Research findings and therapeutic claims are not interchangeable, particularly where human clinical evidence remains limited. (Vasireddi et al., 2025; Therapeutic Goods Administration, 2026).
BPC-157 and safety
Safety is an important area of uncertainty because BPC-157 has not undergone the level of regulatory evaluation associated with an approved medicine. The TGA states that unapproved peptide products have not been evaluated for safety, quality or effectiveness and notes that important information may remain unknown, including how products are manufactured, whether they are sterile, what they contain and whether their labelling accurately describes the product. (Therapeutic Goods Administration, 2026).
The small 2025 intravenous pilot study reported no measurable adverse effects in the two participants studied, but the investigators themselves stated that further studies are needed to confirm the safety of intravenous BPC-157 in humans. A two-person study cannot provide reliable information about uncommon adverse reactions, long-term safety or safety across different populations and formulations. (Lee & Burgess, 2025).
In June 2026, the TGA and Australia’s Chief Medical Officer issued a joint statement concerning the public health risks associated with unapproved peptide products. The statement reported serious adverse effects associated with unapproved peptides, including liver damage, severe allergic reactions requiring hospitalisation, and inflammation and other health complications requiring medical attention. The statement identified BPC-157 among examples of unapproved peptide products. (Therapeutic Goods Administration, 2026).
These reports concern unapproved peptide products generally and should not be interpreted as evidence that every BPC-157 product causes these outcomes. They do, however, demonstrate why the TGA distinguishes between an unapproved product and a therapeutic good that has undergone regulatory assessment. (Therapeutic Goods Administration, 2026).
How is BPC-157 regulated in Australia?
BPC-157 was added to Schedule 4 of the Poisons Standard, with the decision taking effect on 1 June 2024. The final TGA scheduling decision also placed BPC-157 in Appendix D, clause 5, concerning poisons for which possession without authority is illegal. (Therapeutic Goods Administration, 2024).
The TGA’s scheduling decision was based on considerations including the limited available evidence concerning risks and benefits, the experimental nature of BPC-157 and concerns relating to its use as a performance-enhancing substance. The scheduling decision is a classification decision under the Poisons Standard; it is not equivalent to registration or approval of BPC-157 as a medicine. (Therapeutic Goods Administration, 2024).
Is BPC-157 approved by the TGA?
BPC-157 is not included in the ARTG as an approved medicine. The TGA’s current information on unapproved peptide products specifically identifies BPC-157 as an example of an unapproved peptide product. (Therapeutic Goods Administration, 2026).
The ARTG is the TGA’s public register of therapeutic goods that can be legally supplied in Australia, subject to the relevant regulatory requirements and exemptions. A product that is not included in the ARTG is generally an unapproved therapeutic good unless a specific exemption or other lawful pathway applies. (Therapeutic Goods Administration, 2026).
It is therefore important not to describe BPC-157 as a TGA-approved medicine, an ARTG-registered treatment, or a medicine whose safety and effectiveness have been established by the TGA. Its Schedule 4 classification does not change this distinction. (Therapeutic Goods Administration, 2024; Therapeutic Goods Administration, 2026).
What does “unapproved therapeutic good” mean?
An unapproved therapeutic good is a therapeutic good that has not been included in the ARTG. The TGA explains that unapproved goods have not undergone the standard pre-market assessment for safety, quality and effectiveness associated with approved therapeutic goods. Certain unapproved goods may nevertheless be accessed in defined circumstances under Australian regulatory pathways, subject to the applicable requirements. (Therapeutic Goods Administration, 2026).
The existence of a lawful pathway for accessing an unapproved therapeutic good does not convert that product into an ARTG-approved medicine. The product remains unapproved, and the responsibilities of the healthcare practitioner and other parties involved continue to apply. (Therapeutic Goods Administration, 2026).
Does compounding mean BPC-157 is approved?
No. Compounding and ARTG registration are separate regulatory concepts. The TGA states that compounded medicines are not evaluated for safety, quality and efficacy in the same way as ARTG-registered medicines. Certain compounded goods can fall within specific exemptions from ARTG requirements when the applicable conditions are met, but this does not constitute TGA approval of the compounded product. (Therapeutic Goods Administration, 2026).
Whether a particular compounded product can lawfully be prepared or supplied depends on the circumstances and the applicable Commonwealth, state or territory requirements. The regulatory status of the underlying substance should therefore not be described simply as “approved because it can be compounded.” (Therapeutic Goods Administration, 2026).
Why does individual clinical assessment matter?
Ahpra’s guidance on unapproved medicines emphasises that prescribing decisions must involve appropriate clinical reasoning and consideration of the evidence, risks, unknowns and alternatives. Practitioners are also expected to document their decision-making and informed-consent discussions when prescribing unapproved medicines. (Ahpra, 2026).
Ahpra’s published case studies specifically include a case involving the prescribing of unapproved peptides. The case highlights the importance of establishing a clinical reason for using an unapproved medicine, considering appropriate evidence, explaining that the medicine is unapproved and discussing possible risks, unknowns and alternatives with the patient. (Ahpra, 2026).
This means that a person’s interest in BPC-157, information found online, or a request for a particular peptide does not itself establish that the substance is clinically appropriate for that person. Any clinical decision must be made independently by the responsible healthcare practitioner within their professional obligations and the applicable regulatory framework. (Ahpra, 2026).
BPC-157 and Australian advertising rules
Australian advertising rules are particularly relevant to BPC-157 because it is a Schedule 4 substance. The TGA’s current advertising guidance states that the public advertising prohibition for prescription medicines applies to direct and indirect references to Schedule 4 substances. The guidance specifically gives “BPC 157” and “peptides” as examples of references that can fall within these restrictions. (Therapeutic Goods Administration, 2026).
The TGA also states that an advertisement for a health service can be regulated if it directly or indirectly advertises a therapeutic good. This means that simply presenting a BPC-157 reference as part of a service advertisement does not necessarily remove it from therapeutic-goods advertising requirements. (Therapeutic Goods Administration, 2026).
The TGA has increased its compliance focus on unapproved peptide products during 2026. Its published compliance material describes concerns relating to unlawful importation, supply and advertising of unapproved peptides and states that regulatory action is being taken where unlawful activity is identified. (Therapeutic Goods Administration, 2026).
For this reason, educational content about BPC-157 should be carefully separated from promotional claims, testimonials, treatment claims or invitations to obtain the substance. Providing factual information about regulatory status and published research is materially different from representing an unapproved prescription substance as a treatment option. (Therapeutic Goods Administration, 2026).
BPC-157: research versus regulation
| Question | Current position |
|---|---|
| Is BPC-157 a peptide? | Yes. It is a synthetic peptide investigated extensively in preclinical research. |
| Has BPC-157 been studied in humans? | Yes, but the human evidence remains very limited. A 2025 intravenous pilot study involved only two participants. |
| Is BPC-157 included in Schedule 4? | Yes. The TGA’s final scheduling decision took effect on 1 June 2024. |
| Is BPC-157 an ARTG-approved medicine? | No. The TGA identifies BPC-157 as an example of an unapproved peptide product. |
| Does Schedule 4 mean TGA approval? | No. Scheduling and ARTG registration are separate regulatory processes. |
| Does compounding automatically make BPC-157 approved? | No. Compounding does not itself create ARTG registration or TGA approval. |
Frequently Asked Questions
Is BPC-157 approved for use in Australia?
No. BPC-157 is not an ARTG-approved medicine. The TGA currently identifies BPC-157 among examples of unapproved peptide products. (Therapeutic Goods Administration, 2026).
Has BPC-157 been studied in humans?
Yes, but the human evidence is limited. A 2025 pilot study investigated intravenous BPC-157 in two adults, while a 2025 systematic review identified only limited human evidence within the musculoskeletal literature. (Lee & Burgess, 2025; Vasireddi et al., 2025).
Does the research prove that BPC-157 promotes healing?
No. Preclinical studies have reported biological effects associated with tissue repair and healing, but these findings do not establish clinical effectiveness in humans. Larger, controlled human studies are needed to determine whether findings from experimental models translate into clinically meaningful outcomes. (Vasireddi et al., 2025).
Is BPC-157 a prescription-only substance in Australia?
BPC-157 was added to Schedule 4 of the Poisons Standard, effective 1 June 2024. Schedule 4 is the prescription-only classification within the Poisons Standard, with additional requirements applying under the relevant legislation. (Therapeutic Goods Administration, 2024).
Does Schedule 4 mean BPC-157 has been approved by the TGA?
No. Scheduling and ARTG registration are separate regulatory processes. BPC-157 remains an unapproved peptide product rather than an ARTG-registered medicine. (Therapeutic Goods Administration, 2024; Therapeutic Goods Administration, 2026).
Is there enough human research to establish long-term safety?
The available evidence is not sufficient to establish long-term safety. Human studies remain small, and the current literature contains substantially more preclinical research than robust clinical evidence. (Lee & Burgess, 2025; Vasireddi et al., 2025).
Why does the TGA describe BPC-157 as an unapproved peptide?
Because BPC-157 is not included in the ARTG as an approved medicine. The TGA states that unapproved peptide products have not undergone its standard assessment for safety, quality and effectiveness and identifies BPC-157 specifically among examples of unapproved peptide products. (Therapeutic Goods Administration, 2026).
Key takeaway
BPC-157 has a substantial body of preclinical research and a much smaller body of human research. Studies have investigated biological pathways associated with tissue repair, inflammation and other processes, but the current human evidence remains limited. BPC-157 is classified in Schedule 4 of the Australian Poisons Standard and is not an ARTG-approved medicine. (Sikiric et al., 2016; Vasireddi et al., 2025; Therapeutic Goods Administration, 2024; Therapeutic Goods Administration, 2026).
Understanding the difference between research evidence, scheduling and regulatory approval is important when evaluating information about BPC-157. A substance can be extensively discussed in scientific literature without being an approved medicine, and early human research should not be interpreted as equivalent to established clinical evidence. (Therapeutic Goods Administration, 2026; Ahpra, 2026).
Educational disclaimer
This article is provided for general educational and informational purposes only. It is not medical advice and is not a recommendation, endorsement or representation that BPC-157 is safe, effective or appropriate for any particular person or purpose. Research findings should not be interpreted as evidence of TGA approval or established clinical effectiveness.
Information concerning medicines and therapeutic goods can change as regulatory decisions, scientific evidence and government guidance develop. Readers should refer to current information from the Therapeutic Goods Administration and appropriately qualified healthcare practitioners when considering questions concerning medicines or therapeutic goods.
GL Vitality Drips provides consultation coordination and administrative support and does not diagnose, treat or prescribe. Clinical decisions are made independently by appropriately qualified and registered healthcare practitioners in accordance with their professional obligations and applicable Australian requirements.
References
- Australian Health Practitioner Regulation Agency (Ahpra) (2026). Meeting your professional obligations when prescribing off-label, unapproved or compounded medicines — Case studies.
- Lee, E. & Burgess, K. (2025). Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Alternative Therapies in Health and Medicine, 31(5), 20–24.
- Sikiric, P. et al. (2016). Stable gastric pentadecapeptide BPC 157: Novel therapy in gastrointestinal tract. Current Pharmaceutical Design, 22(6), 691–706.
- Therapeutic Goods Administration (2024). Notice of final decisions to amend (or not amend) the current Poisons Standard — ACMS #43, ACCS #37, Joint ACMS-ACCS #35.
- Therapeutic Goods Administration (2026). Understanding your responsibilities when importing, compounding and supplying unapproved peptide products.
- Therapeutic Goods Administration (2026). Concerns regarding the public health risks associated with unapproved peptide products.
- Therapeutic Goods Administration (2026). Complying with the restrictions on advertising prescription medicines to the public.
- Vasireddi, N. et al. (2025). Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal, 21, 485–495.
Related reading
A note on this article
This article is general educational information only. It is not medical advice, and it is not a representation that any substance is safe, effective or approved for any purpose. It is not intended to promote the use, purchase or supply of any therapeutic good. Substances that have not been evaluated by the TGA carry unknown risks, including possible side effects, interactions with other medicines and unknown long-term safety.
GL Vitality Drips is a consultation coordination and administrative support service. We do not diagnose, treat, or prescribe, and GL Vitality Drips does not provide, supply, or grant access to any therapeutic good. Any consultation, assessment or pharmacy dispensing is arranged solely by independent, registered healthcare practitioners and licensed Australian pharmacies, subject to their own eligibility criteria. Not all individuals will be suitable candidates, and no outcome is guaranteed.
